Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

Elad Moisseiev; Anat Loewenstein

doi:10.1038/s41433-019-0584-y

Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

Elad Moisseiev^*, Anat Loewenstein

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Editorial

28 Scopus citations

Original language	English
Pages (from-to)	605-606
Number of pages	2
Journal	Eye
Volume	34
Issue number	4
DOIs	https://doi.org/10.1038/s41433-019-0584-y
State	Published - 1 Apr 2020

Access to Document

10.1038/s41433-019-0584-y

Cite this

@article{23063302d9764805a4a7eab48cf2e1b6,

title = "Abicipar pegol—a novel anti-VEGF therapy with a long duration of action",

author = "Elad Moisseiev and Anat Loewenstein",

year = "2020",

month = apr,

day = "1",

doi = "10.1038/s41433-019-0584-y",

language = "אנגלית",

volume = "34",

pages = "605--606",

journal = "Eye",

issn = "0950-222X",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

AU - Moisseiev, Elad

AU - Loewenstein, Anat

PY - 2020/4/1

Y1 - 2020/4/1

UR - http://www.scopus.com/inward/record.url?scp=85073825661&partnerID=8YFLogxK

U2 - 10.1038/s41433-019-0584-y

DO - 10.1038/s41433-019-0584-y

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 31537893

AN - SCOPUS:85073825661

SN - 0950-222X

VL - 34

SP - 605

EP - 606

JO - Eye

JF - Eye

IS - 4

ER -

Abicipar pegol—a novel anti-VEGF therapy with a long duration of action

Access to Document

Other files and links

Cite this